Managing Anxiety in Pediatric Primary Care (MAPP) Study

This study, called MAPP, is looking at a behavioral intervention (a type of therapy) to help children and teenagers with anxiety. The intervention, named MAPP, is based on exposure therapy strategies, which help people gradually face their fears. The goal is to see if primary care providers (like pediatricians or nurse practitioners) can effectively deliver this brief intervention, called the Anxiety Action Plan (AxAP), to reduce anxiety in young people. This could make it easier for more kids to get help for anxiety, especially where there aren't many mental health specialists. The study plans to enroll 60 participants aged 6 to 17 years old who have elevated anxiety symptoms. Researchers will measure how much anxiety symptoms improve at 2 months and 6 months after the intervention starts. The study's current status is unclear.

Study design
This is an interventional study planning to enroll 60 participants. It is a randomized controlled trial designed to test the feasibility of a behavioral intervention.
What's involved
Youth will be assessed at 2 months (post intervention) and 6 months after they are eligible for the study.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after eligibility is established.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06104904

Managing Anxiety in Pediatric Primary Care (MAPP)

Completed
NAAges 6–17InterventionalTreatment
UConn Health
~64 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:MAPP

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Global Impression Improvement scale
Measured over Youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.
+1 more outcome measured
Anxiety
Anxiety Disorders
1 sites across 1 states
Connecticut1
  • Golda S Ginsburg, PhD · PRINCIPAL_INVESTIGATOR · UConn Health

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

6-17 years of age
Have elevated anxiety symptoms as indicated by a total Screen for Child Anxiety Rated Disorders score between 20 and 55 based on parent and/or child report

Exclusion

Have a medical or psychiatric condition contraindicating participation (e.g., suicidality) based on clinical interview
Are receiving psychosocial mental health treatment for anxiety
  • Clinical Global Impression Improvement scaleYouth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.

    Improvement in anxiety symptoms and related functioning since baseline (a score of 1 or 2 is defined as a responder; scores of 3-7 are defined as non-responders).

  • Primary Care Provider Primary outcomePost intervention (i.e., 2 months after first family enrolled)

    Satisfaction with MAPP: 70% of PCPs endorsing a score of 3 (somewhat helpful) or higher on a question asking "how helpful they perceived the program to be"; scores range from 0 (not at all helpful) to 4 very helpful.